Operational KPIs
No quarterly operational KPIs found in SEC filings for this company.
Citable operating metrics
BMY's latest SEC-sourced operating KPI table includes Abraxane Revenue Growth Reported at 46.00 for 2026-03-31.
| Metric | Period | Value | Basis |
|---|---|---|---|
| Abraxane Revenue Growth Reported | Mar 31, 2026 | 46.00 | quarterly |
| Alliance And Other Revenues | Mar 31, 2026 | 321.00 | quarterly |
| Assets In Early Stage Clinical Development | Mar 31, 2026 | 2649.00 | quarterly |
| Auditor Ratification Votes For | Mar 31, 2026 | 3240.00 | quarterly |
| Business Development Investment | Dec 31, 2023 | -53.00 | quarterly |
| Director Votes For | Mar 31, 2026 | 3240.00 | quarterly |
| Eliquis Revenue | Mar 31, 2026 | 2026.00 | quarterly |
| Eliquis Revenue Growth Reported | Mar 31, 2026 | 46.00 | quarterly |
Source: SEC EDGAR operating KPI disclosure; period Mar 31, 2026; filed Apr 30, 2026; accession 0000014272-26-000008.
Continue research
Follow same-sector companies and source explainers connected to the kpis view.
A factual guide to operating KPIs — the company-specific metrics in filings, why they are not standardized, and how Aerarium Research surfaces them.
A factual guide to deferred revenue, cash collected before revenue is earned, and why the liability can matter for recurring businesses.
A factual guide to working capital, current assets, current liabilities, and the operating cash cycle.
A factual guide to seasonal revenue patterns and comparable (same-store) sales — why year-over-year comparisons matter and what comp sales strip out.